Abstract
Rheumatoid arthritis (RA) is an autoimmune condition causing synovitis, joint dysfunction, and tissue deterioration. This review highlights the pathophysiology of RA, including the involvement of cellular components, cytokines, and oxidative stress, and discusses the increased cardiovascular disease (CVD) risks for RA patients. It also explores the role of lysophosphatidic acid (LPA) in RA progression. Current treatments like Disease-Modifying Anti-Rheumatic Drugs (DMRDs), biological DMARDs, and (Non-steroidal Anti-inflammatory Drugs) NASAIDs along with emerging nanomedicine strategies, are examined. The article emphasizes the potential of nanotechnology in enhancing drug delivery, aiming to improve treatment efficacy and safety for RA. This comprehensive review provides insight into complexity of RA and the promising future of nanomedicine in its management.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
